Ionis Pharmaceuticals Inc IONS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,194

Price:

$37.92
Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Monia Brett P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,630

Price:

$38.05
Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Loscalzo Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,508

Price:

$37.86
Oct 16, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-53

Price:

$38.31
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-125

Price:

--
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

125

Price:

--
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,280

Price:

--
Oct 01, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 01, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 01, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

Filings by filing date

Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,194

Price:

$37.92
Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Monia Brett P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,630

Price:

$38.05
Nov 12, 2024 (filed on Nov 14, 2024)

Insider Name:

Loscalzo Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,508

Price:

$37.86
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-125

Price:

--
Oct 16, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-53

Price:

$38.31
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Swayze Eric

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

125

Price:

--
Oct 15, 2024 (filed on Oct 17, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

11,280

Price:

--
Sep 29, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

15,040

Price:

--
Oct 01, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 01, 2024 (filed on Oct 01, 2024)

Insider Name:

Devers Shannon L.

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (right to buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	2855 Gazelle Court CARLSBAD CA 92010
Tel:	N/A
Website:	https://www.ionis.com
IR:	See website

Key People

Brett P. Monia Chief Executive Officer, Director	Elizabeth L. Hougen Chief Financial Officer, Executive Vice President - Finance	C. Frank Bennett Executive Vice President, Chief Scientific Officer
Joseph T. Baroldi Executive Vice President, Chief Business Officer	Richard S. Geary Executive Vice President, Chief Development Officer	Kyle Jenne Executive Vice President - commercial
Eugene Schneider Executive Vice President, Chief Clinical Development and Operations Officer	Eric E. Swayze Executive Vice President - Research	Patrick R. O'Neil Chief Legal Officer, General Counsel and Corporate Secretary

Business Overview

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Financial Overview

For the nine months ended 30 September 2024, Ionis Pharmaceuticals Inc revenues increased 3% to $478.6M. Net loss decreased 2% to $349.5M. Revenues reflect Ionis operations segment increase of 44% to $478.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.50 to -$2.38.

Employees:	927 as of Feb 15, 2024

Reporting Currency:	U.S. Dollars
Enterprise value:	$4,598M as of Sep 30, 2024
Annual revenue (TTM):	$803.07M as of Sep 30, 2024
EBITDA (TTM):	-$355.93M as of Sep 30, 2024
Net annual income (TTM):	-$358.81M as of Sep 30, 2024
Free cash flow (TTM):	-$370.91M as of Sep 30, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	157,897,287 as of Oct 31, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization